The Future of Pharmaceuticals is Out of This World

             I’m on drugs. And so are you. There are drugs that society can ostensibly do without, but a handful are so vital that they are literally keeping some of us alive today. In between the natural world and the medicine cabinet, biotechnology is making life-saving drugs more effective, affordable, and widely available. This is the story of one blockbuster drug, and how it benefitted from observations in a very unusual laboratory.  The drug is Pembrolizumab. It’s sold under the brand name Keytruda and has become the cornerstone of modern cancer immunotherapy.

Our immune systems are designed to fight infections and disease, including cancer.  A class of white blood cells called T-lymphocytes or T-cells, is the immune system’s weapon that destroys pathogens like viruses and cancer cells (Cleveland Clinic, 2023). The cancerous cells of some solid tumors incorporate a gene known as CD274 (Wikipedia, 2026). Expression of this gene produces a cellular transmembrane protein called the Programmed Death-1 Ligand (PD-L1). PD-L1 interacts with the PD-1 immune checkpoint, a regulatory protein in T cells. Unchecked, this interaction allows cancer cells to shield themselves from T cell attack (Lighter Side of Cancer, 2019). Inhibiting the PD-1 immune checkpoint, as illustrated below, is the basis of Keytruda immunotherapy. Researchers at

Figure 1: In this cell-level illustration, Pembrolizumab inhibits the PD-1 immune checkpoint, blocking PD-L1, and activating the T-cell which results in an immune system response to the cancer.  (Source: Ross RC, Akinde YM, Schauer PR, le Roux CW, Brennan D, Jernigan AM, Bueter M, Albaugh VL., CC BY 4.0 <https://creativecommons.org/licenses/by/4.0>, via Wikimedia Commons)

the Dutch pharmaceutical company Organon started work on a PD-1 inhibitor in 2003. After two corporate acquisitions, Organon’s PD-1 antibody found its way into Merck’s oncology portfolio in 2009 (Wikipedia, 2025). In 2013, the FDA designated Keytruda a Breakthrough Therapy. This accelerated the federal review process and led to Keytruda’s FDA approval in 2014 as the first anti-PD-1 cancer therapy available in the US. Keytruda was subsequently approved for treatment of metastatic non-small cell lung cancer in 2015 (Bhateja, 2016) and has since expanded to treat a long list of cancers, including head, neck, bladder cancer, and more.

Historically, Keytruda has been administered to patients by an intravenous infusion (U.S. Food & Drug Administration). Treatment takes approximately thirty minutes with the patient seated in a chemotherapy clinical setting (Lighter Side of Cancer, 2019). Shortly after FDA approval, Merck sought a new formulation of Keytruda that can be delivered by subcutaneous injection, like a vaccine. Subcutaneous delivery would allow patients to self-administer with a spring-loaded syringe, freeing them from the travel burden and time commitment of the intravenous infusion sessions (Kim, 2022). The original Keytruda formulation was too thick and syrupy to push through a small gauge syringe. A less viscous formulation was necessary. A common approach to subcutaneous delivery is formulating the drug as a crystalline suspension. Neutral Protamine Hagedorn (NPH) insulin, an FDA-approved diabetes drug, is a prime example. Microscopic crystals of insulin protein, binding agents, and preservatives are suspended in an aqueous buffer of water and salts that maintain correct pH and isotonicity (FDA Report, 2026). The suspension is the appropriate viscosity for subcutaneous injection and promotes an extended systemic drug exposure (Drug Bank, 2026). For Keytruda, the key was to come up with a formula that yields crystals of the right size and uniformity. Identifying the conditions for optimal crystallization could take months or years, testing myriad combinations of the 48 known independent process variables – unless there was a shortcut (Reichert, 2019).

During the 1980s, the National Aeronautics and Space Administration initiated the Protein Crystal Growth (PCG) program to test the hypothesis that protein crystals grown in microgravity would be free from dislocations and other lattice defects caused by sinking of heavier components (sedimentation), gravity-induced fluid flows, and other effects (Long, 1992). The crystal lattice could advance uniformly, driven exclusively by diffusion (McPherson, 2015). The first crystal growth experiment flew in the European Spacelab 3 module aboard Space Shuttle Challenger mission STS-51B in April 1985 (Wikipedia, 2025).  NASA replaced these temporary experiments with the more permanent Space Shuttle Protein Crystallization Facility (PCF) in the 1990s. PCF growth trials during the 1998 STS-95 mission of Space Shuttle Discovery yielded insulin crystals that were thirty-four times larger on average than a terrestrially-grown control (Borgstahl, 2001). Larger protein crystals are prized by drug researchers for determining the three-dimensional structure of complex proteins via x-ray crystallography, a major biophysical method used by structural biologists to better understand the protein structural-functional relationship. Larger crystals diffract x-rays with greater resolution and signal to noise ratio (referred to as I/sigma ratio) than smaller crystals, making it easier to solve the protein’s molecular structure (McPherson, 2015). From then on, protein crystal growth in space became a pharmaceutical cottage industry. Pictured below is a variety of protein crystals grown on orbit. Facilities were commissioned aboard Space Station Mir, and eventually, the International Space              

Figure 2: Protein crystals grown on the US Space Shuttle and Russian Mir space station (Source: NASA Marshall Space Flight Center (NASA-MSFC), Public domain, via Wikimedia Commons)

Station (ISS). As of 2022, the ISS has run over 500 protein crystallization experiments and the number continues to climb (Kim, 2022). Merck began sponsoring ISS microgravity crystallization work in the early 2000s and in February 2017, Keytruda was ferried to the ISS by the SpaceX Commercial Re-Supply Service 10 mission (Reichert, 2019). At this point in the story, it’s important to pause and restate the primary benefits of protein crystallization in microgravity, as summarized by Jackson: larger, crystals with fewer defects and greater x-ray diffraction resolution (Jackson, 2024). What’s more, it works for a wide range of molecularly intricate proteins, including enzymes, cellular membrane proteins, and antibodies that are fiendishly difficult candidates for crystallization on earth. However, bigger crystals were not what Merck was looking for in a low-viscosity injectable formulation. In fact, they needed the opposite: a uniform distribution of smaller crystals. How would they achieve this in microgravity crystallization experiments? Fortunately, scientists had made a seminal observation during the space shuttle PCF era a quarter of a century earlier and it would be the key to the new formulation.

              In 2009, Merck merged with the American pharmaceutical company Schering-Plough, perhaps best known for the blockbuster allergy medicine Claritin (Wikipedia, 2024). The merged company did business under the name Merck Sharp & Dome (MSD) (Reichert, 2019). During the early 90s, Schering-Plough sponsored space shuttle PCF experiments. Pertinent to this story was a crystallization experiment aimed at reformulating the hepatitis C drug interferon alpha-2b (brand name Intron A) for low viscosity subcutaneous delivery that was run during the Space Shuttle Discovery STS-70 mission in July 1995 (Reichert, 2019), (Wikipedia, 2025). The PCF process that was employed is known as Temperature Induced Batch Crystallization (McPherson, 2015). TIBC starts with supersaturated protein buffer solution sample that is prepared on the ground. Once on orbit, crystallization begins when the solution temperature is cycled up or down according to a programmed profile that may include periods of constant temperature (dwells) to yield desired crystal properties. (McPherson, 2015).  Protein solubility changes with temperature, and crystals nucleate by diffusion in microgravity over days or weeks, a much longer period than on earth (Reichert, 2019). The Merck team would refer to the Intron A TIBC protocol in the ISS Keytruda crystallization experiments.

The 2017 Keytruda TIBC experiment started on the ground prior to launch. Researchers prepared the experimental solution with supersaturated protein in a buffer with polyethylene glycol PEG (Reichert, 2019).  It was loaded into a lot of 1-ml non-conductive polysulfone vials, each sealed with an aluminum cap. Sealed vials were stacked and assembled in the cylinders that comprise the ISS PCF. Detailed photos of PCF reaction cylinders are on display at the ISS National Laboratory website (Protein Crystallization Facility - ISS National Lab). On board the ISS, the cylinders were loaded in the Microgravity Experiment Research Locker Incubator (MERLIN, pictured below), where they remained 

Figure 3: Microgravity Experiment Research Locker Incubator (MERLIN, Source: NASA, Public domain, via Wikimedia Commons)

for 18 days (Reichert, 2019). The stacked vials form a continuous circuit that conducts heat between the baseplate of the cylinder and the opposite end of the stack. This allowed the MERLIN process controller to ramp the temperature of multiple vial stacks from 4-30C over 48 hours (Reichert, 2019). Following the experiment, the vials were returned to earth on board the SpaceX Dragon capsule in a cargo container maintained at 22C. Crystal samples from the ISS vials were compared to samples from a control experiment run on the ground.  Viscosity measurements of crystalline suspension samples from the ISS and ground experiments showed that, as expected, the ISS suspension was over 30% less viscous (Reichert, 2019). Results of a comparison of crystal size was compelling. A histogram of the distribution of protein crystal size from the ground control experiment revealed two distinct peaks, one at 13 micrometers and the other at 102 (a bimodal distribution). The histogram from the flight experiment had only one peak at 39 micrometers. Clearly, crystallizing Keytruda in microgravity yielded a more uniform distribution of small crystals.

              Microgravity crystallization trials of Keytruda revealed two factors that are required to replicate the desired suspension on earth: suppressing sedimentation and applying engineered temperature gradients. Was the ISS trial worth the hassle? To this question, Reichert remarks that “microgravity research offers researchers an opportunity to generate materials distinct from classical earth-based experiments and provide unexpected results that can change the design and planning of earth-based experiments and processes” (Reichert, 2019). With the help of microgravity, the Keytruda formulation for subcutaneous delivery was FDA approved in 2025 (Wikipedia, 2025). The story of Keytruda is only one chapter in a long history of pharmaceutical research in outer space, and the future is bright. Microgravity protein crystallization experiments have outlived the generations of orbital laboratory studies, and it will likely continue in future trials on commercial space stations beyond the 2030 retirement of the ISS.  

The author is grateful to Dr. Christopher Kane for his contribution to this post.

References

American Diabetes Association. (2019, July 1). Diabetes Day by Day: The History of a Wonderful Thing We Call Insulin. Retrieved from American Diabetes Association: https://diabetes.org/blog/history-wonderful-thing-we-call-insulin

Bhateja, P. (2016, February). Pembrolizumab in Non-Small Cell Lung Cancer. Journal of Targeted Therapies in Cancer, 5(1).

Borgstahl, G. e. (2001, January 12). A Test of Macromolecular Crystallization in Microgravity: Large, Well-Ordered Insulin Crystals. NASA NTRS. Retrieved from https://ntrs.nasa.gov/citations/20010084630

Cleveland Clinic. (2023, January 17). T Cells. Retrieved from Cleveland Clinic: https://my.clevelandclinic.org/health/body/24630-t-cells

Cleveland Clinic. (2024, January 17). Insulin. Retrieved from Clevaland Clinic: https://my.clevelandclinic.org/health/body/22601-insulin

Drug Bank. (2026). NPH Insulin. Retrieved from Drug Bank: https://go.drugbank.com/salts/DBSALT001734

FDA.Report. (2026). HUMULIN N- insulin human injection, suspension STERILE DILUENT- diluent injection, solution. Retrieved from FDA.Report: https://fda.report/DailyMed/f6edd793-440b-40c2-96b5-c16133b7a921

Jackson, K. e. (2024, July 16). An Analysis of Protein Crystals Grown under Microgravity Conditions. Crystals, 14(7). Retrieved from https://doi.org/10.3390/cryst14070652

Kim, S. (2022, November 13). Pharma goes to space: Researchers are capitalizing on microgravity in space to accelerate drug discovery and development. Retrieved from Chemical and Engineering News: https://cen.acs.org/pharmaceuticals/drug-development/Pharma-goes-space-drug-development/100/i40

Lighter Side of Cancer. (2019). How Keytruda Cancer Treatment Works (Update). Retrieved from YouTube: https://www.youtube.com/watch?v=R0ccmAXq4RU

Long, M. (1992, January 1). Large scale crystallization of protein pharmaceuticals in microgravity via temperature change. NASA NTRS. Retrieved from https://ntrs.nasa.gov/citations/19930013459

Long, M. e. (1994, July). Protein crystal growth in microgravity-temperature induced large scale crystallization of insulin. Microgravity Sci Technol, 7(2), 196-202.

McPherson, A. a. (2015). Microgravity Protein Crystallization. NPJ Microgravity, 1. Retrieved from https://www.nature.com/articles/npjmgrav201510

Muley, A. (2024, June 24). Keytruda Receives 40th FDA Approval. Retrieved from Cancer Research Institute: https://www.cancerresearch.org/blog/keytruda-receives-40th-fda-approval

Reichert, P. e. (2019). Pembrolizumab microgravity crystallization experimentation. npj Microgravity, 28(5). doi:https://doi.org/10.1038/s41526-019-0090-3

U.S. Food & Drug Administration. (n.d.). Medication Guide, KEYTRUDA. Retrieved 3 2026, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s188lbl.pdf#page=181

Wikipedia. (2024, October 16). Schering-Plough. Retrieved from Wikipedia: https://en.wikipedia.org/wiki/Schering-Plough

Wikipedia. (2025, December 24). Pembrolizumab. Retrieved from Wikipedia: https://en.wikipedia.org/wiki/Pembrolizumab

Wikipedia. (2025, April 20). STS-51-B. Retrieved from Wikipedia: https://en.wikipedia.org/wiki/STS-51-B

Wikipedia. (2025, July 22). STS-70. Retrieved from Wikipedia: https://en.wikipedia.org/wiki/STS-70

Wikipedia. (2026, January). PD-L1. Retrieved from Wikipedia: https://en.wikipedia.org/wiki/PD-L1

 

 

Comments

Popular posts from this blog

Ingenuity is Timeless

Cooking in 2050: A Journey Through Futuristic Culinary Tech

Disruption in Data Center Design Part III: The Disruptor